What is the primary problem Astek Diagnostics is solving?

Astek focuses on the 'UTI Problem,' where current testing takes 24-72 hours and is often inaccurate. This leads to 47% of patients receiving inappropriate antibiotics, fueling the rise of 'Super Bugs' and costing the US healthcare system billions. Their Jiddu system aims to provide results in just one hour, allowing for immediate, precise treatment.

How does the Jiddu system work technically?

The system uses metabolic activity detection. It captures bacteria from a sample via a microfluidic cartridge, cultivates it for 35 minutes in a conductive media with specific antibiotics, and then measures metabolic activity. A decline in activity indicates the antibiotic is effective, while high activity suggests infection presence.

What is the company's current stage of clinical validation?

As of the deck's publication, Astek had completed 408 tests. They successfully finished a pilot with the University of Maryland Medical Center and were in the midst of an ongoing pilot with MedStar Health, where they achieved 96.97% accuracy. A third pilot with Johns Hopkins was listed as pending for 2024.

What is the revenue model for the hardware?

Astek employs a 'razor and blade' strategy. They charge a $10,000 one-time fee for the Jiddu device and generate recurring revenue through $50 disposable test cartridges. This model is designed to be cost-effective for hospitals while providing predictable cash flow for the company.

What is the expected timeline for an investor exit?

The deck explicitly states that the company has already been approached by strategic investors like BioMerieux and BD. They anticipate becoming a prime acquisition target upon FDA clearance in April 2025, with a potential buyout occurring as early as the first quarter of that year.

Astek Diagnostics Pitch Deck Teardown (2023)

See all 22 slides of the Astek Diagnostics pitch deck — a 2023 Seed deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Astek Diagnostics' 2023 pitch deck is a highly technical, data-driven presentation that successfully navigated the complex Seed-stage healthcare landscape. By focusing on a massive, underserved problem—Urinary Tract Infections (UTIs) and the rise of antimicrobial resistance—the company established immediate clinical relevance. The deck excels by showcasing tangible progress, including a 96.97% accuracy rate in clinical pilots and a clear roadmap for expanding from urine samples to blood and CSF. With $1.4M in grants and $2.6M in prior investment already secured at the time of the deck, Astek…

Key takeaways

The company provides specific clinical accuracy data, showing an improvement from 82.00% to 96.97% across pilot phases (Slide 14).
Astek identifies a significant market pain point: 47% of UTIs are treated with inappropriate antibiotics, contributing to a $55B annual cost for antimicrobial resistance (Slides 6-7).
The Jiddu system is positioned as a recurring revenue model, with a $10K one-time device purchase and $50 per test cartridge (Slide 8).
The deck outlines a robust IP portfolio with one issued patent for the test algorithm and three pending disclosures (Slide 15).
A detailed regulatory and commercial timeline predicts FDA clearance by April 2025 and a potential buyout as early as Q1 2025 (Slides 17-19).
The team is supported by a 10-person advisory board covering specialized fields like urology, microbiology, and regulatory affairs (Slide 13).
The business model relies on outsourcing manufacturing and maintenance to vendors like Key Tech to remain focused on R&D (Slide 19).
Comparable transactions in the space show a median revenue multiple of 9.7x, providing a valuation benchmark for investors (Slide 20).

Executive Summary and Vision

Slides 1-3: The Mission and the Platform

Astek Diagnostics opens with a clear, human-centric cover slide featuring the tagline "Saving Lives Through Antibiotic Sensitivity Precision Diagnostics." This immediately establishes the company as a deep-tech healthcare play. Slide 2, titled "Grand Vision," sets a high-stakes roadmap. While the current focus is on urine-based testing (targeted for Q1 2025), the company plans to expand into CSF (2026), Effluent (2027), and Blood (2028). This is a critical slide for Seed investors because it demonstrates that while the initial entry point is narrow (UTIs), the platform is "Universal" (Slide 3) and has a massive Total Addressable Market (TAM).

Slides 4-5: The Comprehensive Approach

These slides provide the technical 'proof of life' for the expansion mentioned in the vision. For the urine-based test, they cite 408 tests completed with 97% accuracy at the MedStar Health pilot. For the other fluids, they cite specific grant-funded proof-of-concept data: 12 samples for CSF (Henry Jackson Foundation), 12 for Effluent (pending DOD contract), and 59 ICU patients for blood (NSF SBIR Phase 1 grant). By tying each fluid type to a specific pilot or grant, Astek de-risks the future roadmap.

The Problem and Market Opportunity

Slides 6-7: The UTI Problem and Antimicrobial Resistance

Astek presents a compelling case for why their solution is needed now . They cite 8.1 million UTI-caused hospital visits per year in the US and a staggering 47% rate of inappropriate antibiotic treatment. The most effective data point here is the "72h" test processing time for current cultures versus their 1-hour promise. Slide 7 connects this to the broader global crisis of "Super Bugs," noting that the economic cost of antimicrobial resistance (AMR) in the US is approximately $55 billion per year. This shifts the narrative from 'better diagnostic' to 'essential infrastructure for public health.'

The Solution and Technology

Slides 8-11: The Jiddu System

Slide 8 introduces the hardware: the Jiddu system . It highlights four key value propositions: 1-hour results, point-of-care testing, ease of use (automated with disposable cartridges), and cost-effectiveness. The pricing is explicitly stated: "$10K as a one-time device purchase" and "$50 per test cartridge." This transparency is rare in Seed decks and helps investors model the revenue potential immediately.

Slides 9 and 10 walk through the mechanics: placing the sample in a microfluidic cartridge, automated filtering, 35-minute cultivation, and final detection. Slide 11 explains the underlying science: Metabolic Activity Detection . A bar chart shows that while a sample has high metabolic activity, the introduction of effective antibiotics (like Cephalexin) causes that activity to drop to near zero. This visualizes the 'aha' moment of the technology—if the bacteria stop 'breathing,' the drug is working.

Team and Advisory Board

Slides 12-13: Deep Domain Expertise

The team slide (Slide 12) features 9 members, led by CEO Mustafa Al-Adhami. The presence of a dedicated Microbiologist, Bioengineer, and Computer Scientist suggests a balanced technical team. However, Slide 13 is the real 'heavy lifter.' The Advisory Board includes 10 MDs and PhDs from prestigious institutions like Johns Hopkins, University of Maryland, and Harvard. They are categorized by specialty (Urology, Intensive Care, Regulatory Affairs), which signals to investors that the company has the necessary clinical and regulatory guidance to navigate the FDA.

Validation and Intellectual Property

Slides 14-16: Proving the Concept

Slide 14, "Technology Validation," is perhaps the most important slide in the deck. It shows a clear progression of accuracy: 82.00% in the first UMB pilot, rising to 95.60% in the second, and reaching 96.97% in the MedStar pilot. This 'up and to the right' data on accuracy is the ultimate de-risking mechanism for a diagnostic company. Slide 15 details the IP Overview , listing one issued patent for the test algorithm and three pending disclosures for the cartridge and reagents. Slide 16 summarizes the company's momentum: $1.4M in scientific grants, $2.6M from investors (including Y Combinator and Wexford Science + Technology), and a pipeline of 10 pilot partners.

The Investment Case

Slides 17-21: Timeline, Terms, and Exit

Slide 17 provides a timeline through 2025, with a clear goal of FDA Clearance by April 2025 . Slide 18, "Investment Terms," uses placeholders ($XXM) for the current round but specifies the instrument: convertible notes . It also mentions a 33% tax refund for investors via the Biotechnology Investment Incentive Tax Credit (BIITC), a clever 'sweetener' for the deal. Slide 19 explicitly discusses the Exit Strategy , naming potential acquirers like BioMerieux and Qiagen. Slide 20 backs this up with Comparable Transactions , showing that similar companies have been acquired for multiples as high as 59.5x revenue. The deck concludes with an Executive Summary (Slide 21) that reiterates their 95%+ accuracy and their need for funding to complete clinical trials.

What Works and What is Missing

What Works

Data Transparency: The inclusion of specific accuracy percentages from named hospital pilots is incredibly persuasive. · Clear Business Model: The $10k/$50 split makes the path to revenue easy to understand. · Regulatory Roadmap: Tying the exit strategy to the April 2025 FDA clearance date gives investors a clear 'liquidity event' horizon. · Advisory Depth: The 10-person advisory board covers every possible clinical and regulatory hurdle.

What is Missing

Unit Economics: While we see the price ($50/cartridge), we don't see the COGS (Cost of Goods Sold). Investors would want to know the gross margin on those disposables. · Competitive Landscape: The deck mentions 'current testing' is slow, but it doesn't name specific competitors in the rapid diagnostic space (e.g., T2 Biosystems or Accelerate Diagnostics). · Detailed Use of Funds: Slide 21 says the funds are to "finalize platform development," but a more granular breakdown of spend (R&D vs. Clinical Trials vs. G&A) is missing.

Founder Takeaways

1. De-risk with Data: If you are in a technical field, don't just say your product works—show the progression of it working. Astek's slide showing accuracy moving from 82% to 97% tells a story of engineering discipline. 2. Align with Incentives: Mentioning the BIITC tax credit shows that the founders are thinking about the investor's bottom line from day one. 3. The Platform Narrative: Start with a narrow, solvable problem (UTIs) but show a clear technical path to a much larger market (Blood/Sepsis). This provides the 'safety' of a niche and the 'upside' of a giant.

Frequently asked questions

What is the primary problem Astek Diagnostics is solving?: Astek focuses on the 'UTI Problem,' where current testing takes 24-72 hours and is often inaccurate. This leads to 47% of patients receiving inappropriate antibiotics, fueling the rise of 'Super Bugs' and costing the US healthcare system billions. Their Jiddu system aims to provide results in just one hour, allowing for immediate, precise treatment.
How does the Jiddu system work technically?: The system uses metabolic activity detection. It captures bacteria from a sample via a microfluidic cartridge, cultivates it for 35 minutes in a conductive media with specific antibiotics, and then measures metabolic activity. A decline in activity indicates the antibiotic is effective, while high activity suggests infection presence.
What is the company's current stage of clinical validation?: As of the deck's publication, Astek had completed 408 tests. They successfully finished a pilot with the University of Maryland Medical Center and were in the midst of an ongoing pilot with MedStar Health, where they achieved 96.97% accuracy. A third pilot with Johns Hopkins was listed as pending for 2024.
What is the revenue model for the hardware?: Astek employs a 'razor and blade' strategy. They charge a $10,000 one-time fee for the Jiddu device and generate recurring revenue through $50 disposable test cartridges. This model is designed to be cost-effective for hospitals while providing predictable cash flow for the company.
What is the expected timeline for an investor exit?: The deck explicitly states that the company has already been approached by strategic investors like BioMerieux and BD. They anticipate becoming a prime acquisition target upon FDA clearance in April 2025, with a potential buyout occurring as early as the first quarter of that year.

Cover slide of the Astek Diagnostics pitch deck — Seed 2023 — Astek Diagnostics pitch deck, slide 1 (2023)

Astek Diagnostics pitch deck: the facts

Company: Astek Diagnostics
Year: 2023
Stage: Seed
Slides: 22
Sector: Healthcare

Astek Diagnostics pitch deck PDF

The full Astek Diagnostics deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Astek Diagnostics pitch deck was used for

This is Astek Diagnostics’ seed-stage pitch deck from 2023 for its Jiddu system, a benchtop diagnostic platform that confirms bacterial infections and assesses antibiotic sensitivity within about one hour using disposable microfluidic cartridges. The deck focuses on commercializing a urine-based test for urinary tract infections (UTIs) as the first application, with a longer-term vision to expand to cerebrospinal fluid, effluent, and blood. In 2023 Astek closed a $2M seed round to advance development and commercialization of the Jiddu UTI device and fund multiple clinical studies, using this deck (or a close variant) in that process. The teardown analyzes how the deck combines clinical pilot data, grant-backed proof-of-concept work, and a clear regulatory and commercialization plan to persuade institutional seed investors.

Business model: Precision diagnostics company developing a benchtop analyzer and disposable cartridges (Jiddu platform) for rapid infection confirmation and antibiotic susceptibility testing, initially focused on urinary tract infections.

Round: Seed
Year: 2023
Raised: $2M
Lead investor: Wexford SciTech Venture Fund
Investors: Wexford SciTech Venture Fund, Iyana Capital, Maryland Momentum Fund, TEDCO
Founders: Mustafa Al-Adhami
Headquarters: Baltimore, Maryland, United States
Industry: Healthcare diagnostics / Medical devices

Use of funds as presented: Commercialize Astek’s urinary tract infection diagnostic device (Jiddu), including supporting multiple clinical studies to demonstrate effectiveness and move toward market launch.

What the Astek Diagnostics deck got right

Compelling platform narrative from UTI to multi-sample coverage. The deck clearly articulates a universal platform vision in which the Jiddu system moves from an initial urine-based UTI test to CSF, effluent, and blood applications, giving investors a line of sight from a focused beachhead to a broader infection-diagnostics platform.
Early multi-fluid clinical and proof-of-concept data. It presents concrete early data: 408 urine tests with approximately 97% accuracy in a MedStar Health pilot, plus proof-of-concept datasets in CSF (12 samples), effluent (12 samples tied to a pending DOD contract), and blood (59 ICU patients under an NSF SBIR grant), showing systematic validation across fluids even at an early stage.
Strong linkage between clinical problem and value proposition. The UTI problem slides tie Jiddu to significant clinical and economic pain points, including high rates of inappropriate empiric therapy, contribution of UTIs to sepsis cases and deaths, and substantial costs associated with antimicrobial resistance, making the value proposition easy to understand for investors.
Clear device-plus-cartridge revenue model. The solution slide details a straightforward business model—a $10K one-time benchtop device and $50 per test cartridge—highlighting a recurring revenue stream aligned with standard diagnostics economics.
Technically transparent description of the diagnostic workflow. The “How it works” slides walk step-by-step through sample insertion, bacterial capture, microfluidic subdivision, reagent mixing, and rapid detection, making the underlying technology more accessible and supporting differentiation versus slower culture-based approaches.
Credible external validation and grant backing. The deck leverages external validation through references to MedStar Health pilots, an NSF SBIR Phase I grant, a grant from the Henry Jackson Foundation, and a pending DOD contract, signaling institutional confidence and non-dilutive support.

What could have been stronger

Problem slides present dense, poorly sourced statistics. The UTI market problem slides rely heavily on dense, partially illegible statistics (e.g., 47% inappropriate empiric therapy, 68,000 deaths, $55B AMR cost) without clear, cited sources in the deck, which can make it difficult for investors to verify the data and may reduce perceived rigor of the market sizing argument.
Clinical performance data are summarized but not granular. While the deck mentions 408 urine-based tests with approximately 97% accuracy in a MedStar Health pilot and proof-of-concept data in other fluids, it does not (in the provided text) break down sensitivity, specificity, or comparative performance versus gold-standard culture, limiting an investor’s ability to assess clinical robustness and regulatory readiness.
Pricing is stated without a clear adoption and reimbursement model. The solution slide specifies a $10K device and $50 per test cartridge but the excerpt does not show a full economic model (e.g., target settings, expected utilization, payor coverage, or health-economic savings) tied explicitly to these prices, leaving questions about adoption, reimbursement, and scalability.
Grant support not tightly linked to roadmap milestones. Although the deck references active or pending grant support (Henry Jackson Foundation, DOD contract, NSF SBIR), the excerpt does not clarify how far these non-dilutive funds will carry development or what milestones they de-risk, which weakens the linkage between grant-funded work and the equity story.

How an investor would read this deck

What draws attention

Validation of the UTI use case through 408 completed urine tests, with a reported c.97% accuracy in a MedStar Health pilot, offering early clinical evidence for the lead application.
The universal platform vision to extend Jiddu from urine to CSF, effluent, and blood using the same benchtop analyzer and cartridge architecture, which suggests a broader TAM if successfully executed.
The combination of device-plus-cartridge economics, with a one-time device price and recurring cartridge revenue that fits common diagnostics business models.
Existing non-dilutive funding and institutional partnerships (e.g., Henry Jackson Foundation, DOD-related work, NSF SBIR grants, MedStar and ICU studies) that partially de-risk technical and clinical development.
Clear articulation of the AMR and UTI burden, positioning Jiddu as a tool to reduce inappropriate empiric antibiotic use and associated costs and mortality.

Risks that stand out

Technical risk that the platform may not achieve and maintain high accuracy and reliability across multiple sample types (CSF, effluent, blood), which are more complex than urine, potentially limiting the universal platform vision.
Regulatory and clinical risk that pilot and proof-of-concept studies may not translate into pivotal trial success or timely regulatory clearance, especially where sample sizes are currently small (e.g., 12-sample CSF and effluent studies).
Commercial risk that hospitals and clinics may be slow to adopt a new diagnostic workflow requiring a $10K benchtop device and $50 cartridges if reimbursement, staffing, and integration into existing lab processes are not clearly addressed.
Competitive risk from other rapid diagnostic technologies and culture-free AST platforms targeting UTI and sepsis markets, which could erode differentiation if Astek cannot sustain technical or cost advantages.

Questions this deck invites

How do Jiddu’s sensitivity, specificity, and time-to-result compare quantitatively against standard urine culture and competing rapid UTI diagnostics across different patient populations?
What is the detailed regulatory plan and timeline for the UTI indication (e.g., FDA pathways, required clinical trial design and endpoints) and how does current pilot data map to those requirements?
How robust is the microfluidic cartridge supply chain and manufacturing plan, including cost of goods, quality control, and scalability for hospital and clinic volumes?
What evidence exists (or is planned) that rapid antibiotic susceptibility information from Jiddu changes prescribing behavior, reduces inappropriate empiric therapy, or improves clinical outcomes enough to support reimbursement?
Beyond the initial $2M seed round, what capital will be required to achieve regulatory clearance, initial commercialization, and expansion into CSF, effluent, and blood, and what milestones are anticipated at each stage?

What founders can take from the Astek Diagnostics deck

Anchoring a seed pitch on a single high-need, well-defined indication (UTIs) while clearly articulating a broader multi-sample platform vision can make the story both focused and expansive.
Including early pilot data (such as hundreds of urine tests and proof-of-concept studies backed by recognized institutions and grants) strengthens credibility even when full pivotal trials are not yet complete.
Combining device and consumable pricing in the deck gives investors a concrete view of the revenue model, but it is more persuasive when tied directly to workflow, utilization, and reimbursement assumptions.
Explicitly connecting non-dilutive funding (grants and contracts) to specific technical and clinical milestones can demonstrate capital efficiency and reduce perceived risk for equity investors.
Presenting a clear, stepwise explanation of how the technology works—from sample loading to bacterial capture and antibiotic testing—helps non-technical investors understand the differentiation in complex diagnostic platforms.
Highlighting the human and economic burden (e.g., costs, mortality, AMR growth) is persuasive when it is coupled with a credible mechanism by which the product can measurably impact those metrics.

Astek Diagnostics pitch deck: common questions

What does Astek Diagnostics do?

Astek Diagnostics is a Baltimore-based precision diagnostics company developing the Jiddu platform, a benchtop analyzer plus disposable cartridges designed to confirm bacterial infections and provide antibiotic sensitivity results within about one hour, initially focused on urinary tract infections (UTIs).

What is the main focus of Astek’s seed pitch deck?

The seed deck is built around the UTI use case, highlighting that Jiddu can detect UTIs and provide antibiotic susceptibility information in one hour, compared with 24–72 hours for standard urine cultures. It presents pilot data from a MedStar Health study, proof-of-concept work in CSF, effluent, and blood supported by grants, and a plan to use the seed funding to complete development, run clinical trials, and move toward commercialization.

How much did Astek raise in its seed round and who invested?

According to a 2023 funding announcement, Astek raised $2M in seed funding to commercialize its UTI diagnostic device. The round was led by the Wexford SciTech Venture Fund, with participation from Iyana Capital, the Maryland Momentum Fund, and TEDCO.

How does the Jiddu system work, based on the deck?

The deck describes Jiddu as a benchtop analyzer using specialized microfluidic cartridges: the sample is loaded into a disposable cartridge, bacteria are captured via an automated filtration process, then the sample is subdivided into channels with control and antibiotic-containing reagents, and within about 15 minutes the device can detect bacterial presence and generate antibiotic sensitivity results for pre-selected antibiotics. External materials similarly describe Jiddu as identifying bacterial infection in urine and performing antibiotic susceptibility testing within an hour.

What is the long-term vision for Jiddu beyond UTIs?

Later materials describe Astek as planning to bring the Jiddu Analyzer’s urine test to market around 2025, with a broader vision to support multiple sample types (urine, CSF, effluent, blood) over time. These timelines and expansions are forward-looking goals and not yet outcomes at the time of the 2023 seed deck.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

Astek Diagnostics pitch deck slides

Astek Diagnostics pitch deck slide 1 of 22 — Astek Diagnostics pitch deck — slide 1 of 22

Astek Diagnostics pitch deck slide 2 of 22 — Astek Diagnostics pitch deck — slide 2 of 22

Astek Diagnostics pitch deck slide 3 of 22 — Astek Diagnostics pitch deck — slide 3 of 22

Astek Diagnostics pitch deck slide 4 of 22 — Astek Diagnostics pitch deck — slide 4 of 22

Astek Diagnostics pitch deck slide 5 of 22 — Astek Diagnostics pitch deck — slide 5 of 22

Astek Diagnostics pitch deck slide 6 of 22 — Astek Diagnostics pitch deck — slide 6 of 22

What each slide of the Astek Diagnostics pitch deck says

Slide 2

oils Grand Vision Current Focus i Delivery Roadmap : Urine i CSF Effluent Blood g Q1 2025 2026 2027 2028 oe EXPECTED FDA APPROVAL TIMELINE .

Slide 3

Universal Platform While Astek Diagnostics has prioritized going to market first with a urine-based test, its vision is for the Jiddu system to confirm bacterial infections and assess antibiotic sensitivity across 4 sample types: urine, CSF, effluent, and blood. Hﬂﬂi Urine CSF Effluent Blood

Slide 4

Comprehensive Approach Urine > UTi confirmation and antibiotic sensitivity in 1 hour. » 408 urine-based tests already completed with increasingly high accuracy over time (c.97% accuracy level currently achieved: Medstar Health pilot). CSF » Meningitis confirmation and antibiotic sensitivity in 1 hour. » Proof of concept data with 12 samples has already been accumulated as part of an active grant from the Henry Jackson Foundation.

Slide 5

Comprehensive Approach (Cont'd) Effluent ] » Surgical site infection confirmation and antibiotic sensitivity in 1 hour. » Proof of concept data with 12 samples has already been accumulated in advance of ramping up work on this fluid as part of a pending DOD contract. Blood » Bacteremia confirmation and antibiotic sensitivity test in 1 hour. » Proof of concept data from a study involving 59 ICU patients has already been accumulated with the company as part of an active NSF SBIR Phase 1 grant.

Slide 6

Current Focus: The UTI Problem UTI-caused hospital visits per $168 of annual cost from mistreated UTis 0, 47% treated with inappropriate Empiric therapy causes antibiotic resistant 47% nbiotics® bactra to incrase by 300% parannum 25% 25% of sepsis cases 68,000 lives lost @ per annum in the US alone 0 arecaused by UTIs @ as a result of UTi-related sepsis cases 72h testprocessingforurine cultures takes 24-72 hrs Current testing is slow accuracy of dipstick 50% ool 0ot o e ey s 0 by L€ g e P o2 )Lk T e S

Slide 7

Current Focus: The UTI Problem & Mainly caused by ¥ Leadstotheemergence & The economic cost of overuse and misuse of new and more i AMRin the US alone is of antimicrobials resistant strains of estimated at c$55 bacteria billion per year Inadequate diagnostics * Improper antibiotic prescription '. Development of resistant strains & v serious complications like sepsis . —— Even harder infections + Inadequate diagnostics

Slide 8

The Solution: The Jiddu system HO) 1-Hour Results ¢ » Rapid UTI detection 7o » Antibiotic sensitivity indication ® Point-of-Care Testing + Actionable results » Expedited treatment Ease of Use » Basic trainin requirement » Automated testing & Disposable cartridges Cost effective ' > $10K as a one-time device purchase > $50 pertest cartridge (recurring revenue stream)

Slide 9

How it works [ i 1) Place the sample into the cartridge The sample s placed in a specialized microfluidic cartridge. The type of cartridge utilized varies with the sample type. Once attached, the cartridge is placed in the device and the automated testing process begins. 2 Bacteria from the sample is captured Through an automated fltering process, the bacteria is captured from the sample. Far the blood panel, this capturing process incorporates step to eliminate hemoglabin from lysed blood cells.

Slide 10

How it works (Cont'd) Cultivation and antibiotic testing The sampl ubdivided into multiple channe to be mixed wi control channels. Once divided a Detection of bacteria presence reagents before moving mber. After 15 minutes, the device can confirm via in the sample as well as provide sults for the pre-selected antibiotics.

Slide text above is read directly from the Astek Diagnostics deck PDF embedded on this page.